Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Earnings for Autolus Therapeutics plc (AUTL)
Earnings in 2023 (TTM): $-208,402,000
According to Autolus Therapeutics plc's latest financial reports the company's current earnings (TTM) are $-208,402,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Autolus Therapeutics plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-208,402,000 | $-208,383,000 |
| 2022 | $-173,205,000 | $-148,839,000 |
| 2021 | $-165,988,000 | $-142,096,000 |
| 2020 | $-166,257,000 | $-142,094,000 |
| 2019 | $-139,008,000 | $-123,849,000 |
| 2018 | $-36,326,659 | $-31,114,488 |
| 2017 | $-23,380,000 | $-19,727,000 |
| 2016 | $-14,327,000 | $-12,550,000 |
| 2015 | $-8,098,657 | $-7,464,150 |